Vulvovaginitis - candidal
Methodology & AI Transparency ⓘ
Vulvovaginitis - candidal Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code B37.31 in Infections & Antivirals, Vulvovaginitis - candidal requires sepsis/severity red-flag triage [Vulvovaginitis - candidal B37.31] so specialists can calibrate treatment intensity against Targeted PCR / in Vulvovaginitis - candidal (B37.31: Culture & Sensitivity) benchmarks.
- 2 Real-world patient consensus: Diagnostic registry B37.31: Vulvovaginitis - candidal is managed within Infections & Antivirals.
- 3 Typical cash cost range: Clinicians assessing Vulvovaginitis - candidal focus on localized inflammatory exudate [Vulvovaginitis - candidal B37.31] and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Vulvovaginitis - candidal: Targeted PCR / in Vulvovaginitis - candidal (B37.31: Culture & Sensitivity) (Pathogen clearance / negative test (B37.31)) and Complete Blood Count in Vulvovaginitis - candidal (B37.31: (WBC & Differential)).
Ask our AI Specialists anything about Vulvovaginitis - candidal
What Is Vulvovaginitis - candidal?
Cataloged under federal diagnostic code B37.31 in Infections & Antivirals, Vulvovaginitis - candidal requires sepsis/severity red-flag triage [Vulvovaginitis - candidal B37.31] so specialists can calibrate treatment intensity against Targeted PCR / in Vulvovaginitis - candidal (B37.31: Culture & Sensitivity) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Vulvovaginitis - candidal (ICD-10 B37.31) is driven by localized inflammatory exudate [Vulvovaginitis - candidal B37.31]; specialists in Bacterial, Viral & Fungal Infections monitor Complete Blood Count in Vulvovaginitis - candidal (B37.31: (WBC & Differential)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Vulvovaginitis - candidal (B37.31): sore throat, productive in Vulvovaginitis - candidal (B37.31: cough, sinus/ear pain,)
- • Secondary Vulvovaginitis - candidal clinical sign: painful vesicular rash in Vulvovaginitis - candidal (B37.31: in a dermatomal)
- • Symptom flares in Vulvovaginitis - candidal correlating with Targeted PCR / in Vulvovaginitis - candidal (B37.31: Culture & Sensitivity) deviation outside Pathogen clearance / negative test (B37.31)
- • Functional infections & antivirals impact requiring sepsis/severity red-flag triage [Vulvovaginitis - candidal B37.31] evaluation (B37.31)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Vulvovaginitis - candidal Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B37.31 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Targeted PCR / in Vulvovaginitis - candidal (B37.31: Culture & Sensitivity) | Pathogen clearance / negative test (B37.31) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Vulvovaginitis - candidal (B37.31: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B37.31) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Vulvovaginitis - candidal (B37.31: Procalcitonin) | Resolution to baseline (B37.31) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Vulvovaginitis - candidal
Treatment selection for Vulvovaginitis - candidal depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Vulvovaginitis - candidal)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Population how the body absorbs the medicine Evaluation of Amikacin Liposome Systemic exposure to amikacin in serum and urine following once-daily ALIS administration in patients with treatment-refractory NTM lung disease was notably lower than that previously reported for parenteral amikacin. European journal of drug metabolism and pharmacokinetics • 2021-03-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 33595792 ↗ |
Vulvovaginitis - candidal Patient Community & “People Like Me” Threads
Filter Vulvovaginitis - candidal community threads and patient logs by age, biological sex, dosage, and treatment duration.